TNFSF12 and rheumatoid arthritis: The efficacy of BIIB023 (phase II) is now explored in the ongoing clinical trial ATLAS (Anti-TWEAK in Lupus Nephritis patients) for patients with lupus nephritis, a pathology that requires a more innovative treatment than RA.